| Bioactivity | HBV-IN-45 is a selective and orally active HBV capsid assembly modulator with an IC50 of 0.51 μM for HBcAg in HBC cells. HBV-IN-45 shows potent anti-HBV activities[1]. |
| Invitro | HBV-IN-45 (compound 26f) 抑制 HepG2 细胞的生长，CC50 值为 84.29 μM。HBV-IN-45 还可抑制 HepAD38 细胞上清液中的 HBV DNA，EC50 为 2.24 μM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> HBV-IN-45 相关抗体: |
| In Vivo | HBV-IN-45（compound 26f；100 mg/kg；口服；每日两次；持续14天）抑制血浆中 HBV DNA 数量，小鼠血清中 HBeAg 和肝酶 GPT（ALT）无差异[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C16H16N2O2S |
| Molar Mass | 300.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kaixin Du, et al. Development of benzimidazole-based compounds as novel capsid assembly modulators for the treatment of HBV infection. Eur J Med Chem. 2024 Apr 16:271:116402. |